Investigational Drug Information for BMS-986278
✉ Email this page to a colleague
What is the drug development status for BMS-986278?
BMS-986278 is an investigational drug.
There have been 12 clinical trials for BMS-986278.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 14th 2023.
The most common disease conditions in clinical trials are Pulmonary Fibrosis, Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Bristol-Myers Squibb and [disabled in preview].
There are two US patents protecting this investigational drug and fifty-one international patents.
Summary for BMS-986278
| US Patents | 2 |
| International Patents | 51 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-09-14) |
| Vendors | 16 |
Recent Clinical Trials for BMS-986278
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | Bristol-Myers Squibb | Phase 3 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Bristol-Myers Squibb | Phase 3 |
| A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants | Bristol-Myers Squibb | Phase 1 |
Clinical Trial Summary for BMS-986278
Top disease conditions for BMS-986278
Top clinical trial sponsors for BMS-986278
US Patents for BMS-986278
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BMS-986278 | ⤷ Sign Up | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | Bristol-Myers Squibb Company (Princeton, NJ) Syngene International Limited (Bangalore, Karnataka, IN) | ⤷ Sign Up |
| BMS-986278 | ⤷ Sign Up | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | Bristol-Myers Squibb Company (Princeton, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BMS-986278
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BMS-986278 | Argentina | AR108838 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | Australia | AU2017281439 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | Australia | AU2021209334 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | Brazil | BR112018076558 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | Canada | CA3029202 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | Chile | CL2018003708 | 2036-06-21 | ⤷ Sign Up |
| BMS-986278 | China | CN109963843 | 2036-06-21 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
